Clinical trials: Heart Failure, Congestive
Arrhythmia, Cardiovascular Diseases
Diagnostic Investigation of Sudden Cardiac Event Risk
The overall objective of the DISCERN study is to develop and validate a genomic diagnostic assay to identify patients at increased risk for lethal ventricular arrhythmias and sudden cardiac death (SCD).
- Conditions
- Arrhythmia, Cardiovascular Diseases, Heart Failure, CVD
- Trial name
- DISCERN (NCT00500708)
- Where
- 8 sites in United States
- Volunteers
- 1,564 people
- Sponsor
- CardioDx
Heart Failure
Furosemide Pharmacodynamics and Pharmacokinetics After Subcutaneous or Oral Administration
The purpose of this pilot study is to investigate the pharmacodynamic and pharmacokinetic parameters of a novel furosemide formulation administered subcutaneously as compared to oral furosemide.
- Trial name
- FUROPHARM-HF (NCT02350725)
- Testing
- Furosemide injection solution for subcutaneous administration (80 mg), Oral Furosemide tablets (80 mg)
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- scPharmaceuticals, Inc.
Heart Failure
Study to Collect High-Resolution ECG Data and Patient Insights on Heart Failure Care
The purpose of this study is to establish an electrocardiogram (ECG) data library to facilitate future studies on heart disease.
- Trial name
- NCT06809686
- Where
- 2 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Richmond Research Institute
Heart Failure
Safety, Pharmacokinetic and Pharmacodynamic Study of COR-1, an Anti-ß1 Receptor Antibody Cyclopeptide
Primary Trial objectives: To evaluate the pharmacokinetics and -dynamics of five strengths of COR-1 (10, 40, 80, 160, 240 mg) in 50 healthy, male volunteers after single intravenous administration (8 subjects on verum per dose…
- Trial name
- COR-1-01 (NCT01043146)
- Testing
- COR-1
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Corimmun GmbH
Heart Failure, Cardiovascular Diseases
Nene Remote Monitoring Proof of Concept
This feasibility study is being conducted to investigate the practicalities and potential benefits of equipping patients with wearable monitoring devices.
- Conditions
- Heart Failure, Cardiovascular Diseases, Respiratory Disease, Stroke
- Trial name
- NCT04598659
- Where
- United Kingdom
- Volunteers
- 180 people
- Sponsor
- Doccla UK
Congestive Heart Failure
EarlySense Monitoring Device Evaluation on CHF Patients
CHF patients will be monitored using EarlySense ES-16 device and will simultaneously fill diaries and log their weight daily. The data collected and analyzed by the ES-16 device will be correlated with the CHF status data.
- Trial name
- NCT00382746
- Testing
- EarlySense monitoring device
- Where
- Israel
- Sponsor
- EarlySense Ltd.
Hypertension, Pulmonary, Ventricular Dysfunction, Left
A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction
The aim of this study is to assess whether single oral doses of Riociguat safely improve the cardiovascular function in patients with pulmonary hypertension associated with left ventricular diastolic dysfunction
- Trial name
- DILATE (NCT01172756)
- Testing
- Riociguat (BAY63-2521)
- Where
- 7 sites in Austria, Czechia and 1 more
- Volunteers
- 39 people
- Sponsor
- Bayer
Healthy Volunteers, Heart Failure
A Study Understanding How Much CDR132L Enters the Bloodstream After Injection Under the Skin Compared to Injection Into a Vein in Healthy Participants
This study is being done to understand how much of the medicine (CDR132L) enters the bloodstream after injection under the skin compared to injection into a vein in healthy people.
- Trial name
- NCT07656454
- Testing
- CDR132L (i.v.), CDR132L (s.c.)
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Heart Failure
Study of Organ Perfusion With Custodiol-N Solution Compared With Custodiol Solution in Heart Transplantation
The objective of this investigation is to demonstrate non-inferiority in outcome of Custodiol-N against Custodiol in heart transplantation.
- Trial name
- NCT02869022
- Testing
- Custodiol-N, Custodiol, organ perfusion for heart transplantation
- Where
- 9 sites in Austria, Germany
- Volunteers
- 105 people
- Sponsor
- Dr. F. Köhler Chemie GmbH
Edema, Cardiac
A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)
To evaluate the efficacy and safety of 7-day repeated oral administration of OPC-41061 15 mg or placebo in congestive heart failure (CHF) patients with extracellular volume expansion despite the use of a conventional diuretic.
- Trial name
- NCT00462670
- Testing
- OPC-41061(Tolvaptan)
- Where
- 8 sites in Japan
- Volunteers
- 110 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Cardiac Edema
Efficacy and Safety Study of Tolvaptan to Treat Patients With Cardiac Edema
A randomized, double-blind, multicenter, placebo-controlled, parallel study to evaluate the efficacy and safety of Tolvaptan in the treatment of patients with cardiac edema (body fluid retention caused by congestive heart…
- Trial name
- NCT01651156
- Testing
- Tolvaptan
- Where
- China
- Volunteers
- 244 people
- Sponsor
- Otsuka Beijing Research Institute
Heart Failure, Cognitive Impairment
HeartMapp: Assessment and Treatment for Heart Failure
In the current application, the investigators propose to elaborate upon, reconstruct and advance to pivotal trial readiness a recently validated mobile application (HeartMapp), designed for the ecological momentary assessment and…
- Trial name
- HeartMapp (NCT03827954)
- Testing
- HeartMapp+CT
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Posit Science Corporation
Advanced Heart Failure
A Prospective, Multicenter,Single-arm Study of DuoCor 2 Ventricular Assist System for the Treatment of Advanced Biventricular Heart Failure
The objective of this clinical investigation is to evaluate the safety and efficacy of the DuoCor 2 Ventricular Assist System (DuoCor 2 VAS) in subjects with advanced biventricular heart failure requiring circulatory support.
- Trial name
- NCT07757451
- Testing
- DuoCor 2 Ventricular Assist System (DuoCor 2 VAS)
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Shenzhen Core Medical Technology CO.,LTD.
Congestive Heart Failure
Evaluating Clinical Trial Experiences of Individuals With Congestive Heart Failure
Clinical trial participation has always been substantially skewed toward certain demographic groups. However, there has been little study on whether trial qualities impact participation in either a positive or negative way.
- Trial name
- NCT05516290
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Risk Reduction
Effect of Dapagliflozin Plus Low Dose Pioglitazone on Hospitalization Rate in Patients With HF and HFpEF
The prevalence of type 2 diabetes mellitus (T2DM) in Qatar and nations worldwide has increased in recent decades into epidemic proportions. Cardiovascular (CVD) disease is the leading cause of death in T2DM patients.
- Trial name
- NCT03794518
- Testing
- Pioglitazone Plus dapaglifliozin
- Where
- Qatar
- Volunteers
- 648 people
- Sponsor
- Hamad Medical Corporation
Ischemic Heart Failure
LifeVest Wearable Cardioverter Defibrillator WEARIT-III Registry
The WEARIT-III registry enrolls subjects with ischemic cardiomyopathy and heart failure (including NYHA II, III, IV and an ejection fraction ≤ 35%) who wear a medically prescribed ZOLL LifeVest Wearable Defibrillator.
- Trial name
- WEARIT-III (NCT02700880)
- Testing
- LifeVest
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Zoll Medical Corporation
Acute Decompensated Heart Failure, Fluid Overload
A Feasibility Study on Ultrafiltration and Blood Volume Measurements
The objective of this feasibility study is to characterize the performance of the Aquadex FlexFlow® System with the hematocrit (HCT) feature in conjunction with Daxor's blood volume analyzer (BVA-100).
- Trial name
- NCT04241718
- Testing
- Aquadex FlexFlow System and BVA-100
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Nuwellis, Inc.
Heart Failure
Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency
The purpose for this study (CY 1124) is to evaluate the effects of CK-1827452, a cardiac myosin activator, on myocardial systolic performance, myocardial oxygen consumption, and myocardial efficiency in patients with heart…
- Trial name
- NCT00748579
- Testing
- CK-1827452
- Where
- 3 sites in United States, Canada
- Volunteers
- 2 people
- Sponsor
- Cytokinetics
Heart Failure
Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure
The primary objective of this study is to monitor the safety profile of Jardiance® in Korean patient with chronic heart failure (New York Heart Association (NYHA) class II-IV) in a routine clinical setting.
- Trial name
- NCT05236673
- Testing
- JARDIANCE®
- Where
- 21 sites in South Korea
- Volunteers
- 676 people
- Sponsor
- Boehringer Ingelheim
Sleep Apnea
Mapping for Acute Transvenous Phrenic Nerve Stimulation Study
The Mapping for Transvenous Phrenic Nerve Stimulation Study (MAPS) is being conducted to evaluate the feasibility of transvascular stimulation of phrenic nerves via an electrophysiology (EP) catheter advanced into the great veins.
- Trial name
- MAPs (NCT01981590)
- Testing
- Stimulating the phrenic nerve intravenously using high frequency electrical pulses using an EP catheter connected to external pulse stimulator.
- Where
- 2 sites in Netherlands, Sweden
- Volunteers
- 15 people
- Sponsor
- Medtronic BRC